Patients with ankylosing spondylitis are associated with an increased risk of developing neurodegenerative diseases, ...

Alterity Therapeutics Limited (NASDAQ:ATHE – Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 148,600 shares, ...

Researchers at the University of Illinois have found that a gene editing tool allows them to “skip” genes that lead to ...

The global neuro immunoassay market is projected to experience significant growth, with a valuation of US$ 2,616.1 million in ...

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.

Pridopidine hydrochloride is under clinical development by Prilenia Therapeutics Development and currently in Phase III for Huntington Disease.

A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce ...

A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...

A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...

Dancing lowers the depression associated with Parkinson's disease, and the benefits can be seen in multiple ways, a new study shows. Dancing lowers the depression associated with Parkinson disease, ...

Roche has announced results from the Phase IIb PADOVA study evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease. Wh ...